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http://dx.doi.org/10.1016/j.jinf.2012Summary Objectives: To determine the prevalence of cryptococcal antigenemia in a UK HIV
cohort and compare baseline characteristics of patients with and without cryptococcal antige-
nemia.
Methods: Stored sera were retrospectively tested for cryptococcal antigen (CRAG) among
newly diagnosed HIV-infected persons with CD4 < 100 cells/mL, who presented to Croydon Uni-
versity and St George’s Hospitals, London, between January 2004 and October 2010. We as-
sessed risk factors for cryptococcal antigenemia and patient outcomes by extracting
demographic and clinical information from medical records.
Results: 157 patients were identified with a median age of 47 and CD4 count of 26 cells/mL. 102
(65%) were of Black race and 91 (58%) of African origin. Eight patients (5%) had positive serum
CRAG. 7/8 had cryptococcal meningitis (CM) as first presentation of HIV, and 1 had sub-clinical
infection. 7/8 (88%) CRAG positives were of African origin compared to 84/149 (54%) of CRAG
negatives (p Z 0.14). Other baseline characteristics did not differ significantly.
Conclusion: We found a 5% prevalence of cryptococcal antigenemia in newly diagnosed HIV pa-
tients with CD4 < 100 cells/mL in southwest London, the first such data for a UK HIV cohort.
Cryptococcal antigenemia occurred almost exclusively in African-born individuals. Weciation conference, Birmingham UK 18e20 April 2012 and published as abstract in HIV Medicine
of Infection and Immunity, St George’s University of London, Blackshaw Road, London SW17 0RE, UK.
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tients with CD4 < 100 cells/mL.
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Cryptococcalmeningitis (CM) is amajoropportunistic infection
and a leading cause of mortality in HIV-infected patients
throughout the world, causing an estimated 600,000 deaths
annually, particularly in resource-limited countries.1 Treat-
ment remains inadequate, with 10-week mortality between
20 and 40%, even with optimal current antifungal combina-
tions.2 CM usually occurs at an advanced stage of immunosup-
pression, with median CD4 count below 50 cells/mL in large
cohorts from developed and developing countries.3,4
In Europe and North America, introduction of antiretro-
viral therapy (ART) has been associated with a decline in CM
incidence. However, in resource-limited countries, where
patients frequently present late with advanced disease and
CD4 count below 100 cells/mL, disease burden remains high
despite availability of ART.2,5
Exposure to Cryptococcus neoformans is thought to be
universal. The organism is inhaled from the environment,6
and genotypic evidence suggests acquisition can occur
many years before the development of clinical cryptococ-
cosis in the context of immunosuppression.7 Cryptococcal
antigenemia (presence of cryptococcal capsular polysac-
charide antigen (CRAG) in blood), can precede onset of
CM by weeks to months,8 and presents an opportunity for
early intervention with pre-emptive fluconazole therapy
to prevent development of CM.
In Africa, the reported prevalence of cryptococcal
antigenemia in HIV patient cohorts with CD4 counts below
100 cells/mL ranges from 2 to 13%.8e13 In a South African
ART program, a pre-ART serum CRAG test at a titre 1:2
had a 28% positive predictive value for development of in-
cident CM in the first year of ART, and was an independent
predictor of mortality.9
Compared to the cost of CM hospitalisation and treat-
ment, CRAG screening and fluconazole treatment are cost-
effective in resource-limited settings,11,14 with one study
estimating the screen-and-treat strategy to be cost-saving
above a CRAG prevalence of 3%.11 Routine screening of all
newly diagnosed patients with CD4 < 100 cells/mL using
a novel point-of-care dipstick CRAG test (www.immy.
com/products/), prior to ART initiation, is currently being
piloted in South Africa15 and Uganda [NCT01535469].
Due to lack of prevalence data for newly diagnosed HIV
patients in the United Kingdom, British HIV Association
(BHIVA) Opportunistic Infection guidelines16 recommend se-
rum CRAG screening only in those with symptoms suggestive
of cryptococcosis and CD4 count < 200 cells/mL.
We aimed to determine the prevalence of cryptococcal
antigenemia in newly diagnosed HIV patients with
CD4 < 100 cells/mL in an urban Southwest London popula-
tion. Our HIV clinic population is multiracial and interna-
tional, with a high proportion of patients originating from
Sub-Saharan Africa and significant numbers presenting late
with advanced HIV at diagnosis. We also sought to compare
baseline characteristics of patients with and withoutcryptococcal antigenemia, in order to establish whether
screening should be targeted at any specific groups.
Patients and methods
This was a retrospective cohort study conducted between
April and October 2011 at Croydon University (previously
Mayday) Hospital and St George’s Hospital in London. Newly
diagnosed patients were identified from clinic and laboratory
databasesusing the inclusioncriteria: i) age18years; ii) new
confirmed positive HIV serology diagnosed for the first time
between January 2004 to October 2010, with stored serum or
plasma available for testing; iii) CD4 count < 100 cells/mL;
iv) not yet on ART at time of stored blood sample.
The studywasapprovedby theUKNationalResearchEthics
committee and the Research and Development Office of St
George’s Hospital NHS Trust. St George’s Hospital Virology
laboratory stores serum for 2 years and plasma (HIV viral
loads) for up to 10 years. Given theuse of retrospective stored
samples, plus a requirement for samples to be at least 6
months old prior to testing (to allow patients to have become
establishedonART, such that any retrospectivepositive result
would not impact current clinical care), the requirement for
informed consent was waived.
Stored serum or plasma samples from time of initial HIV
diagnosis were anonymised prior to testing. CRAG testing
was performed on serum or plasma using the Cryptococcal
Latex Agglutination test (Immuno-Mycologics Inc, USA), an
antibody-agglutination reaction detecting the capsular
polysaccharide antigen of C. neoformans with a specificity
and sensitivity of >95%. Samples were incubated with Pro-
nase(Roche) at 56 C for 15 min and analysed according to
manufacturers’ instructions. All samples were screened un-
diluted and at a 1:100 dilution. Any samples with a titre of
1:2 were defined as positive, and serially diluted twofold
to determine the CRAG titre.
Demographic and clinical data, including CD4 count at
HIV diagnosis, age, sex, ethnic group, country of origin and
sexual orientation, were obtained from clinic databases by
clinicians independent from the laboratory researchers. For
any patients with cryptococcal antigenemia detected on
retrospective testing of stored serum or plasma, clinical
presentation at HIV diagnosis, results of relevant investiga-
tions, antifungal treatment, time to start of ART and
development of incident or relapsed CM in the first 6
months on ART were obtained from medical notes and
laboratory results review. Data were analysed using Graph-
Pad Prism v5 (GraphPad Software, USA), using the t-test to
compare continuous variables and the Fisher’s exact test
for categorical variables.
Results
One hundred fifty seven patients fulfilled the inclusion
criteria, of whom 87 (55%) were male, 128 (82%)
Cryptococcal antigenemia in HIV SW London 77heterosexual and 26 (17%) MSM. At HIV diagnosis, median
(IQR) age was 47 (39e53) years and CD4 count was 26
(11e55) cells/mL.
One hundred two (65%) patients were of Black Race,
predominantly Black African (n Z 86, 55%). Race notwith-
standing, to take into account environmental exposure to
C. neoformans, 91 (58%) were from Africa, including 3
White and 2 Asian patients, and 39 (25%) were from the
UK; other regional groupings were the West Indies
(n Z 10), mainland Europe (n Z 7), Asia (n Z 5) and Latin
America (n Z 4).
Eight (5%) stored serum samples tested retrospectively
were positive for CRAG. On case note and laboratory results
review, 7 of these were patients who had presented with
CM as their first manifestation of HIV, and one was deemed
to have sub-clinical infection (mild headache, serum CRAG
titre performed at presentation 1:2; CSF microscopy, pro-
tein and glucose normal, CRAG 1:2 and C. neoformans cul-
tures negative). African-origin patients had a serum CRAG
prevalence of 8% (7/91). CM was the HIV-presenting illness
in 4% (7/157) of the entire cohort, and 7% (6/91) of patients
from Africa.
Table 1 compares demographic and clinical data for
CRAG positive and negative patients. There were no signif-
icant differences between CRAG positive and negative
groups in terms of age, CD4 count or ethnicity. All but
one of the CRAG positives were from Africa: 7/8 (88%), in-
cluding 6 Black African heterosexuals and one White South
African MSM, compared with 84/149 (54%) of CRAG nega-
tives (p Z 0.14).
Table 2 shows the CSF parameters and clinical course of
the 8 CRAG positive patients. All were admitted to hospital
(4 were transfers into St George’s from local district general
hospitals). The 7 patients with CM all presented with head-
ache and were diagnosed by lumbar puncture (LP). All re-
ceived a 2-week course of amphotericin B and flucytosine
and were maintained on fluconazole for a median of 11
months. ART was started at a median (range) of 4 (4e32)
weeks post CM diagnosis. One patient was lost to follow-up
and the other 6 followed up for a median of 30 months post
CM diagnosis: all were known to be alive at 6 months and 5
of 6 at 1 year (1 transferred their care at 8 months). Two of
6 experienced CM symptom recurrence compatible with im-
mune reconstitution inflammatory syndrome (IRIS), with
negative CSF C. neoformans cultures, at 2 and 8 months
from start of ART respectively: both were re-admitted and
received a course of steroids, with resolution of symptoms.
The only patient with sub-clinical infection received
fluconazole prophylaxis alone (400 mg/d for 10 weeks, then
200 mg/d). This patient reported headaches in the earlyTable 1 Comparison of demographic and clinical data for CRAG
CRAG positiv
N 8
Sex male n (%) 5 (63)
Heterosexual, n (%) 6 (75)
Age (y), median (IQR) 38 (25e43)
CD4/mL at diagnosis, median (IQR) 34 (5e64)
Black race, n (%) 6 (75)
African origin, n (%) 7 (88)months of ART, but did not receive an LP, and these
resolved by 12 weeks on ART. Fluconazole was stopped
after 10 months and he remained asymptomatic for
a further year of follow-up.Discussion
To our knowledge, this is the first study to assess the
prevalence of cryptococcal antigenemia in a UK HIV-
infected patient cohort. At two hospitals in Southwest
London comprising an international population with an
African heterosexual predominance, there was a 5% prev-
alence of cryptococcal antigenemia in newly diagnosed
patients with CD4 count < 100 cells/mL. Almost all of the
CRAG positive patients were African, though the statistical
power of the comparison of proportion of African patients
between the CRAG positive (88%) and negative (54%) groups
was limited by the cohort size.
This relatively high prevalence of cryptococcal infection,
on a par with some African countries, reflects our African HIV
patient predominance, and may not be generalizable to all
UK HIV cohorts. Our numbers may also have been augmented
by a tertiary centre referral bias of complex HIV patients
with advanced disease and CM for specialist Infectious
Diseases inpatient care. Four of the 8 patients had been
transferred to St George’s from hospitals in our sector, for
whom we did not have a new HIV diagnoses denominator.
Excluding those transfers would result in a conservative
estimate of prevalence of cryptococcal infection in newly
diagnosed HIV patients with CD4< 100 cells/mL in southwest
London of 3% (4/153), and 5% (4/84) in Africans.
In our cohort, almost all the CRAG positive patients were
only diagnosed with HIV at the time of presentation with
CM. Late HIV diagnoses are not exclusive to resource-
limited countries: in 2010, 28% of new UK HIV diagnoses
had CD4 counts < 200 cells/mL17 and in North America in
2008, 33% of newly HIV-diagnosed patients developed AIDS
within one year.18 By ethnicity, late presentation is highest
amongst Black Africans,17 and the National Institute for
Clinical Excellence is promoting increased HIV testing in
this group.19 For our African CRAG positive patients with
known time between arrival to the UK and new HIV diagno-
sis, this ranged from 5 to 16 years, suggesting opportunities
for earlier HIV diagnosis and ART, which might have pre-
vented dissemination of latent cryptococcal infection oc-
curring at lower CD4 counts.
For those diagnosed late, the question remains whether
CRAG screening at HIV diagnosis should be routinely
recommended. To be effective, screening needs to bepositive and negative groups.
e CRAG negative p-Value
149
82 (55) 0.73
122 (82) 0.64
42 (34e48) 0.15
26 (12e55) 0.85
96 (64) 0.47
84 (54) 0.14
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78 S. Patel et al.done prior to symptomatic presentation within the anti-
genemic window, which ranges from weeks to months.8
Current BHIVA guidelines20 recommend excluding crypto-
coccal infection in symptomatic patients with CD4 < 200
cells/mL but do not advocate routine screening or flucona-
zole prophylaxis. CM is not a reportable disease: HPA figures
of new CM diagnoses in the UK between 2006 and 2011
range from 5 to 28 cases/year, suggesting significant under-
reporting [C Chau, Health Protection Agency HIV&STI de-
partment, personal communication]. Based on these
figures and our relatively high prevalence in a London co-
hort, it is difficult to extrapolate to recommendations for
targeted screening in the UK.
However a new, highly sensitive and specific point-of-
care dipstick CRAG lateral flow assay21 costs just £4 per
test,22 and the cost of fluconazole at 400 mg/d is £5/month
(St George’s NHS price). On the other hand, the cost of an-
tifungal drugs alone for a 2-week course of CM treatment is
£10,000 (based on a 70 kg adult, using Liposomal Amphoter-
icin B and flucytosine as per BHIVA recommendations,16 St
George’s NHS price). Using our conservative prevalence es-
timate of 5% in Africans with CD4 count < 100 cells/mL,
screening 100 patients would cost £400 to identify 5 CRAG
positives. Following a recently proposed algorithm for
asymptomatic cryptococcal antigenemia,23 these would re-
quire pre-emptive fluconazole therapy until CD4
count > 200 cells/mL: 12 months’ treatment of 5 patients
would cost approximately £300. This approach would thus
be highly cost-effective (total cost £700) even if just one
case of CM (£10,000) were to be prevented, notwithstand-
ing the prevention of morbidity and mortality associated
with development of CM.
In summary, the prevalence of cryptococcal antigenemia
in newly diagnosed patients with CD4 < 100 cells/mL in
a Southwest London HIV cohort is on a par with many
resource-limited countries and was most frequent in Afri-
cans regardless of race. Late HIV presentation remains
common in the UK, particularly in Black Africans. CRAG
screening using new tests and fluconazole treatment is
significantly less expensive than the treatment of CM. We
would therefore recommend integrating CRAG screening of
African HIV-infected patients with CD4 count < 100 cells/mL
with national efforts to increase HIV testing in this late-
presenting group who, globally as well as in this UK HIV
cohort, appear to bear the largest cryptococcal meningitis
disease burden.
Conflicts of interest
All authors have no conflicts of interest to disclose.
Source of funding
Wellcome Trust Intermediate Fellowship to T Bicanic,
WT089966.Acknowledgements
Cryptococcal antigen latex kits were kindly donated by Immy
diagnostics (Immuno-Mycologics, Inc, Norman, OK, USA).
Cryptococcal antigenemia in HIV SW London 79References
1. Park BJ, Wannemuehler KA, Marston BJ, Govender N,
Pappas PG, Chiller TM. Estimation of the current global burden
of cryptococcal meningitis among persons living with HIV/AIDS.
AIDS 2009;23:525e30.
2. Jarvis JN, Bicanic T, Harrison TS. Management of cryptocococcal
meningoencephalitis inbothdevelopedanddevelopingcountries.
In: Heitman J, et al., editors.Cryptococcus neoformans: fromhu-
man pathogen to model yeast. ASM Press; 2011 [chapter 42].
3. Van der Horst CM, Saag MS, Cloud GA, Hammill RJ, Graybill R,
Sobel JD, et al. Treatment of cryptococcal meningitis associ-
ated with the acquired immunodeficiency syndrome. N Engl J
Med 1997;337:15e21.
4. Bicanic T, Muzoora C, Brouwer A, Meintjes G, Longley N,
Taseera K, et al. Rate of clearance of infection is indepen-
dently associated with clinical outcome in HIV-associated cryp-
tococcal meningitis: analysis of a combined cohort of 262
patients. Clin Infect Dis 2009;49:702e9.
5. Castelnuovo B, Manabe YC, Kiragga A, Kamya M, Easterbrook P,
Kambugu A. Cause-specific mortality and the contribution of
immune reconstitution inflammatory syndrome in the first 3
years after antiretroviral therapy initiation in an urban African
cohort. Clin Infect Dis 2009;49:965e72.
6. Velagapudi R, Hsueh YP, Geunes-Boyer S, Wright JR, Heitman J.
Spores as infectious propagules of Cryptococcus neoformans.
Infect Immun 2009;77:4345e55.
7. Garcia-Hermoso D, Janbon G, Dromer F. Epidemiological evi-
dence for dormant Cryptococcus neoformans infection. J Clin
Microbiol 1999;37:3204e9.
8. French N, Gray K, Watera C, Nakiyingi J, Lugada E, Moore M,
et al. Cryptococcal infection in a cohort of HIV-1 e infected
Ugandan adults. AIDS 2002;16:1031e8.
9. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS.
Screening for cryptococcal antigenemia in patients accessing
an antiretroviral treatment program in South Africa. Clin Infect
Dis 2009;48:856e62.
10. Liechty CA, Solberg P, Were W, Ekwaru JP, Ransom RL,
Weidle PJ, et al. Asymptomatic serum cryptococcal antigene-
mia and early mortality during antiretroviral therapy in rural
Uganda. Trop Med Int Health 2007;12:929e35.
11. Meya DB, Manabe YC, Castelnuovo B, Cook BA, Ebireer AM,
Kambugu A, et al. Serum cryptococcal antigen (CRAG) screen-
ing is a cost-effective method to prevent death in HIV-infected
persons with CD4 100/uL starting HIV therapy in resource-
limited settings. Clin Infect Dis 2010;51:448e55.
12. Mamoojee Y, Shakoor S, Gorton RL, Sarfo S, Appiah LT,
Norman B, et al. Short Communication: low seroprevalence
of cryptococcal antigenaemia in patien ts with advanced HIV
infection enrolling in an antiretroviral programme in Ghana.
Trop Med Int Health 2011;16:53e6.13. Desmet P, Kayembe KD, De Vroey C. The value of cryptococcal
serum antigen screening among HIV-positive/AIDS patients in
Kinshasa, Zaire. AIDS 1989;3:77e8.
14. Jarvis JN, Harrison T, Lawn S, Meintjes G, Wood R, Cleary S.
Cost effectiveness of cryptococcal antigen screening as a strat-
egy to prevent HIV-associated cryptococcal meningitis in South
Africa. IAS Rome, 2011, WELBD02-Oral Abstract.
15. Govender N. 18th Congress of the International Society for
Human and Animal Mycology, Berlin, 11e15 June 2012,
abstract C3.
16. Nelson M, Manji H, Wilkins E. Central nervous system opportu-
nistic infections. British HIV Association and British Infection
Association Guidelines for the Treatment of Opportunistic In-
fection in HIV-seropositive Individuals 2011. HIV Med 2011;
12(Suppl. 2):8e24.
17. Health Protection Agency. HIV in the United Kingdom: 2011
Report. Available at: http://www.hpa.org.uk/Publications/
InfectiousDiseases/HIVAndSTIs/1111HIVintheUK2011report;
2011. National Institute of Clinical Excellence. Increasing the
uptake of HIV testing to reduce undiagnosed infection and pre-
vent transmission among black African communities living in
England. Available at: http://guidance.nice.org.uk/PH33;
2011.
18. Chen M, Rhodes PH, Hall IH, Kilmarx PH, Branson BM,
Valleroy LA. Centers for disease control and prevention
(CDC). Prevalence of undiagnosed HIV infection among persons
aged 13 yearsdNational HIV Surveillance System, United
States, 2005-2008. MMWR Morb Mortal Wkly Rep 2012 Jun
15;61(Suppl):57e64.
19. National Institute of Clinical Excellence. Increasing the uptake
of HIV testing to reduce undiagnosed infection and prevent
transmission among black African communities living in En-
gland, http://guidance.nice.org.uk/PH33; 2011.
20. Asboe D, Aitken C, Boffito M, Booth C, Cane P, Fakoya A, et al.
British HIV Association guidelines for the routine investigation
and monitoring of adult HIV-1-infected individuals 2011. HIV
Med 2012;13:1e44.
21. Jarvis JN, Percival A, Bauman S, Pelfrey J, Meintjes G,
Williams GN, et al. Evaluation of a novel point-of-care crypto-
coccal antigen test on serum, plasma and urine from patients
with HIV-associated cryptococcal meningitis. Clin Infect Dis
2011;53:1019e23.
22. Alpha Laboratories. Crytpcococcal Antigen Systems.
Available at: www.alphalabs.co.uk/product-information/
diagnostic-products/mycology/cryptococcal-antigen-systems.
aspx [accessed 22.06.12].
23. Jarvis JN, Govender N, Chiller T, Park BJ, Longley N, Meintjes
G, et al. Cryptococcal antigen screening and pre-emptive
therapy in patients initiating antiretroviral therapy in
resource-limited settings: a proposed algorithm for clinical
implementation. J Int Assoc Physicians AIDS Care (Chic) 2012
Sep 26. [Epub ahead of print].
